Sign In
Buy TAK
$17.09
-0.160 (-0.93%)
At Close: Jul 31, 2026
TAK vs. DSNKY: Which Stock Is the Better Value Option?
12:46pm, Monday, 17'th Feb 2025
Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
10:45am, Friday, 14'th Feb 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
08:30am, Friday, 31'st Jan 2025
Takeda Pharmaceutical offers attractive dividends and has a low price/book ratio, making it appealing despite recent price drops and US policy uncertainties. The company reported strong Q3 earnings, r
Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript
04:45pm, Thursday, 30'th Jan 2025
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - Pr
Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge
09:00am, Thursday, 30'th Jan 2025
BOSTON--(BUSINESS WIRE)--Suffolk, one of the largest and most innovative real estate and construction enterprises in the country, recently celebrated topping off 585 Kendall. Designed by CBT Architect
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
02:04am, Thursday, 30'th Jan 2025
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Ta
Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates
01:43am, Thursday, 30'th Jan 2025
Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as the company continues a restructuring push.
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advanceme
- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator - Takeda Reacquires Ri
Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO
07:14pm, Thursday, 23'rd Jan 2025
Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.
Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO
06:24am, Tuesday, 21'st Jan 2025
China-based Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin
Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors
08:00am, Saturday, 07'th Dec 2024
Takeda Pharmaceutical offers a high dividend yield, but its sustainability is questionable due to exchange rate risks and a payout ratio often exceeding 100%. Despite growth in segments like Livtencit
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
12:37pm, Tuesday, 03'rd Dec 2024
On Tuesday, Takeda Pharmaceutical Company Limited TAK entered into an exclusive licensing agreement with Keros Therapeutics, Inc. KROS to further develop, manufacture and commercialize elritercept
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
07:00am, Tuesday, 03'rd Dec 2024
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to f
